Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Marketwire (May 8, 2013)
-
Marketwire (May 7, 2013)
-
-
-
Marketwire (Apr 16, 2013)
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Onyx Pharmaceuticals: Profit Ramp AheadWilliam Meyers • Mon, Jan 7 -
-
-
-
-
3 Reasons To Buy Onyx PharmaceuticalsMarkus Aarnio • Sun, May 27, 2012
-
Onyx Pharmaceutical: Highest Returning Protected Covered CallMike Phillips • Thu, Apr 26, 2012 -
Onyx's Myeloma Drug Shifts To The Slow LaneEP Vantage • Tue, Dec 13, 2011 -
Onyx: Deal Or No Deal, Time For A PayoffProhost Biotech • Tue, Nov 29, 2011 -
Onyx Pharma's Prospects Look BrightWilliam Meyers • Thu, Aug 18, 2011
-
Higher-Than-Expected Loss at OnyxZacks Investment Research • Thu, May 5, 2011 -
Onyx Pharma's Future Getting BrighterZacks Investment Research • Fri, Mar 18, 2011
-
-
-
-
Onyx Pharmaceuticals Inc. Q2 2009 Earnings Call TranscriptTue, Aug 4, 2009
-
Onyx Pharmaceuticals Inc. Q1 2009 Earnings Call TranscriptWed, May 6, 2009
-
Onyx Pharmaceuticals, Inc., Q4 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
ONYX Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptFri, Nov 7, 2008
-
Onyx Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Onyx Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptTue, May 6, 2008
-
Onyx Pharmaceuticals Inc., Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
Onyx Pharmaceuticals Q3 2007 Earnings Call TranscriptTue, Nov 6, 2007
-
Marketwire (May 8, 2013)
-
Marketwire (May 7, 2013)
-
Marketwire (Apr 16, 2013)
-
Marketwire (Feb 27, 2013)
-
Marketwire (Feb 21, 2013)
-
Marketwire (Feb 5, 2013)
-
Marketwire (Jan 16, 2013)
-
Marketwire (Jan 15, 2013)
-
at CNBC.com (Jan 13, 2013)
-
at CNBC.com (Jan 7, 2013)
-
at CNBC.com (Jan 7, 2013)
-
Marketwire (Jan 2, 2013)
-
Marketwire (Dec 17, 2012)
ONXX vs. ETF Alternatives
Company Description
We are a biopharmaceutical company dedicated to developing innovative therapies that target the molecular mechanisms that cause cancer. Through our internal research programs and in conjunction with our collaborators, we are applying our expertise to develop and commercialize therapies designed... More
